392 related articles for article (PubMed ID: 23819994)
41. Hepatitis B virus X protein modulates remodelling of minichromosomes related to hepatitis B virus replication in HepG2 cells.
Luo L; Chen S; Gong Q; Luo N; Lei Y; Guo J; He S
Int J Mol Med; 2013 Jan; 31(1):197-204. PubMed ID: 23128981
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of long-term interferon therapy in chronic hepatitis B patients with HBV genotype C.
Sakai T; Shiraki K; Inoue H; Okano H; Deguchi M; Sugimoto K; Ohmori S; Murata K; Nakano T
Int J Mol Med; 2002 Aug; 10(2):201-4. PubMed ID: 12119559
[TBL] [Abstract][Full Text] [Related]
43. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels.
Pollicino T; Amaddeo G; Restuccia A; Raffa G; Alibrandi A; Cutroneo G; Favaloro A; Maimone S; Squadrito G; Raimondo G
Hepatology; 2012 Aug; 56(2):434-43. PubMed ID: 22271491
[TBL] [Abstract][Full Text] [Related]
44. [Quantitative detection of intrahepatic hepatitis B virus DNA in patients with chronic hepatitis B].
Lu H; Ma LX; Xu WS; Zhang HY; Yu LJ; Duan HY
Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):173-5. PubMed ID: 12681068
[TBL] [Abstract][Full Text] [Related]
45. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection.
Lucifora J; Arzberger S; Durantel D; Belloni L; Strubin M; Levrero M; Zoulim F; Hantz O; Protzer U
J Hepatol; 2011 Nov; 55(5):996-1003. PubMed ID: 21376091
[TBL] [Abstract][Full Text] [Related]
46. Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy.
Lin CL; Liao LY; Wang CS; Chen PJ; Lai MY; Chen DS; Kao JH
Liver Int; 2004 Feb; 24(1):9-15. PubMed ID: 15101995
[TBL] [Abstract][Full Text] [Related]
47. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection.
Marinos G; Naoumov NV; Williams R
Hepatology; 1996 Nov; 24(5):991-5. PubMed ID: 8903365
[TBL] [Abstract][Full Text] [Related]
48. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
Herbers U; Amini-Bavil-Olyaee S; Mueller A; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
[TBL] [Abstract][Full Text] [Related]
49. Hepatitis B virus: new therapeutic perspectives.
Lin CL; Yang HC; Kao JH
Liver Int; 2016 Jan; 36 Suppl 1():85-92. PubMed ID: 26725903
[TBL] [Abstract][Full Text] [Related]
50. Response of pre-core mutant chronic hepatitis B infection to lamivudine.
Rizzetto M; Volpes R; Smedile A
J Med Virol; 2000 Jul; 61(3):398-402. PubMed ID: 10861653
[TBL] [Abstract][Full Text] [Related]
51. The current status and future directions of hepatitis B antiviral drug discovery.
Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT
Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587
[TBL] [Abstract][Full Text] [Related]
52. Interferon-stimulated gene of 20 kDa protein (ISG20) degrades RNA of hepatitis B virus to impede the replication of HBV in vitro and in vivo.
Leong CR; Funami K; Oshiumi H; Mengao D; Takaki H; Matsumoto M; Aly HH; Watashi K; Chayama K; Seya T
Oncotarget; 2016 Oct; 7(42):68179-68193. PubMed ID: 27626689
[TBL] [Abstract][Full Text] [Related]
53. Inhibitory effects of metachromin A on hepatitis B virus production via impairment of the viral promoter activity.
Yamashita A; Tamaki M; Kasai H; Tanaka T; Otoguro T; Ryo A; Maekawa S; Enomoto N; de Voogd NJ; Tanaka J; Moriishi K
Antiviral Res; 2017 Sep; 145():136-145. PubMed ID: 28827084
[TBL] [Abstract][Full Text] [Related]
54. Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription.
Deng JJ; Kong KE; Gao WW; Tang HV; Chaudhary V; Cheng Y; Zhou J; Chan CP; Wong DK; Yuen MF; Jin DY
Biochim Biophys Acta Gene Regul Mech; 2017 Apr; 1860(4):491-501. PubMed ID: 28242208
[TBL] [Abstract][Full Text] [Related]
55. Hepatitis B virus hijacks CTHRC1 to evade host immunity and maintain replication.
Bai L; Zhang W; Tan L; Yang H; Ge M; Zhu C; Zhang R; Cao Y; Chen J; Luo Z; Ho W; Liu F; Wu K; Wu J
J Mol Cell Biol; 2015 Dec; 7(6):543-56. PubMed ID: 26180054
[TBL] [Abstract][Full Text] [Related]
56. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).
Revill P; Locarnini S
Curr Opin Pharmacol; 2016 Oct; 30():144-150. PubMed ID: 27639371
[TBL] [Abstract][Full Text] [Related]
57. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.
Durantel D; Zoulim F
J Hepatol; 2016 Apr; 64(1 Suppl):S117-S131. PubMed ID: 27084032
[TBL] [Abstract][Full Text] [Related]
58. Management of hepatitis B: our practice and how it relates to the guidelines.
Yapali S; Talaat N; Lok AS
Clin Gastroenterol Hepatol; 2014 Jan; 12(1):16-26. PubMed ID: 23660419
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus.
Liu Y; Zhao M; Gong M; Xu Y; Xie C; Deng H; Li X; Wu H; Wang Z
Antiviral Res; 2018 Apr; 152():58-67. PubMed ID: 29458131
[TBL] [Abstract][Full Text] [Related]
60. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.
Guo JT; Guo H
Antiviral Res; 2015 Oct; 122():91-100. PubMed ID: 26272257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
